Journal of Cardiovascular Pharmacology

SEPTEMBER 4, 2023

However, most of the available evidence for efficacy is from small clinical trials with inflammatory and cardiorenal biomarker endpoints, rather than cardiovascular event endpoints, or from small CKD subgroups in larger clinical trials.

Kidney Disease 40

Kidney Disease Transplant Atherosclerosis Biomarkers 40

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

European Journal of Heart Failure

DECEMBER 1, 2023

A mixed model repeated measurements model (MMRM) was used to evaluate the effect of empagliflozin vs. placebo on the analysed biomarkers.

Heart Failure 40

Heart Failure Biomarkers Kidney Disease Atrial Fibrillation 40

Frontiers in Cardiovascular Medicine

FEBRUARY 13, 2024

By comparing myocardial injury patients with non-myocardial injury patients, notable differences were observed in age, pre-existing medical conditions (e.g.,

Risk Factors 64

Risk Factors Laboratory Coronary Artery Disease Cerebrovascular Disease 64

Cardiometabolic Health Congress

JULY 25, 2024

Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. The future of care demands a holistic approach.

Education 100

Education Innovation Risk Factors Obesity 100

Cardiometabolic Health Congress

AUGUST 8, 2024

Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g., Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,

Education 59

Education Cardiovascular Disease Diabetes Kidney Disease 59

European Journal of Heart Failure

NOVEMBER 23, 2023

Abstract Aims Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease. In a subgroup of patients (n = 349) without concomitant hypertension, diabetes mellitus or chronic kidney disease, albuminuria was also associated with mortality (HR=2.98, 95%CI[1.72-5.17],

Kidney Disease 40

Kidney Disease Article Biomarkers Heart Failure 40

Open Heart

JULY 17, 2023

to 5.12; p=0.049), chronic kidney disease (HR 1.89; 95% CI 1.03 to 3.49; p=0.041) as well as severe valvular heart disease (HR 3.08; 95% CI 1.68 Results The combined end point of death and emergency cardiovascular hospitalisation occurred in 70 (36.3%) of 193 patients with a postponed cardiovascular intervention.

COVID-19 52

COVID-19 Outcomes Cardiovascular Interventions Risk Factors 52

Circulation

NOVEMBER 11, 2024

However, multi-parametric techniques and biomarkers which are available for investigating cardiovascular diseases and kidney diseases may offer opportunities for the evaluation of CRS. Conclusion:The FeUa seems to be a negative predictor of CRS in patients hospitalized with ADHF.

Heart Failure 40

Heart Failure Kidney Disease Laboratory Hospital 40

DAIC

JANUARY 23, 2024

14,15 Similarly, the NLRP3 inflammasome has been implicated in pathogenesis as it leads to the activation of proinflammatory cytokines triggering robust proinflammatory signaling through interleukin-6 (IL-6) and inducing production of C-reactive protein (CRP), a biomarker for inflammation.16 34 The safety of colchicine, 0.5 μ/L on 0.6

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

GEMMS

MAY 22, 2024

Much of heart disease is linked to conditions like diabetes, obesity, or chronic kidney disease, and specific mutations in nucleic acids help identify them. Genetic testing and DNA sequencing improve the accuracy of predicting heart disease risk.

Heart Disease 52

Heart Disease Blood Pressure Technology Innovation 52

Stroke Journal

JANUARY 30, 2025

Introduction:Chronic kidney disease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.

Kidney Disease 40

Kidney Disease Hemorrhage Risk Factors Heart Disease 40

Stroke Journal

FEBRUARY 1, 2024

Introduction:Chronic kidney disease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH. In this study, we examined the relationship between ICH and CKD, as well as intracranial arterial calcification (IAC) as an intermediate biomarker.

Kidney Disease 40

Kidney Disease Hemorrhage Risk Factors Biomarkers 40

European Journal of Heart Failure

AUGUST 24, 2023

CKD, chronic kidney disease; HFrEF, heart failure with reduced ejection fraction; Hb, hemoglobin; Htc, hematocrit; Fe - Intravenous iron; Sat, saturation; SGLT2i - sodium-glucose co-transporter 2 inhibitor. Secondary outcomes included changes in natriuretic peptides, kidney function and heart failure-associated outcomes.

Heart Failure 40

Heart Failure Kidney Disease Biomarkers Outcomes 40

Cardiometabolic Health Congress

SEPTEMBER 13, 2024

Measuring eGFR and albuminuria is recommended for assessing kidney disease in all hypertensive patients. Below are some of the most notable highlights: 2024 ESC Updated Clinical Guidelines: Key updates include clopidogrel as a first-line option for long-term use after MI or PCI. REVERSE-FLOW Trial: Prof.

Hypertension 59

Hypertension Cardiovascular Disease Bicuspid/Mitral Arrhythmia 59

Stroke Journal

JANUARY 30, 2025

Background and Purpose:Chronic kidney disease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025.

Atherosclerosis 40

Atherosclerosis Kidney Disease Blood Pressure Biomarkers 40

Frontiers in Cardiovascular Medicine

JANUARY 29, 2025

ObjectiveTo investigate the sex differences in the efficacy of renal denervation (RDN) in patients with resistant hypertension (RHT) concerning the size of abdominal fat depots, changes in biomarkers of sympathetic activity, and renal function.Materials and methods24 men (56.57.8 years) and 33 women (59.58.4 In men, the eGFR did not change.

Obesity 52

Obesity Hypertension Kidney Disease Blood Pressure 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. .” In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103

Open Heart

JANUARY 4, 2025

AKI was defined using Kidney Disease Improving Global Outcomes (KDIGO) AKI criteria. Differential uAGT response in patients receiving RAS blockers with ongoing AKI suggests biomarkers may be helpful in predicting treatment responses and cardiorenal outcomes.

Heart Failure 40

Heart Failure Outcomes Kidney Disease Transplant 40

Dr. Smith's ECG Blog

FEBRUARY 26, 2025

Both reperfusion, as judged by the biomarker curve, and patency, as assessed by the angiogram, were correlated with the rapidity and depth of T wave inversion. The only other processes identified that caused this type of postinfarction T wave evolution were cardiopulmonary resuscitation, reinfarction, and very small infarcts.

Chest Pain 89

Chest Pain Pericarditis Myocardial Infarction Dementia 89